AstraZeneca PLC has inked a collaboration with Silence Therapeutics PLC to develop gene-silencing drugs for cardiovascular, renal, metabolic and respiratory diseases, a deal that will transform the UK biotech's clinical and financial future.
Silence will be responsible for designing small interfering RNA (siRNA) molecules against gene targets initially against liver-based targets, as well as developing new delivery approaches to target the heart, lung and kidney